ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GDR Genedrive Plc

1.65
0.025 (1.54%)
28 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.025 1.54% 1.65 1.60 1.70 1.70 1.625 1.63 27,752,936 15:13:46
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 55k -5.15M -0.0095 -1.74 8.96M
Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 1.63p. Over the last year, Genedrive shares have traded in a share price range of 1.425p to 17.50p.

Genedrive currently has 543,141,481 shares in issue. The market capitalisation of Genedrive is £8.96 million. Genedrive has a price to earnings ratio (PE ratio) of -1.74.

Genedrive Share Discussion Threads

Showing 6176 to 6194 of 27075 messages
Chat Pages: Latest  255  254  253  252  251  250  249  248  247  246  245  244  Older
DateSubjectAuthorDiscuss
08/2/2021
23:49
now appears that BGF now have their shares cleared ,
bunz3
08/2/2021
22:44
There could still be a back test to the pound... buy the dips
losses
08/2/2021
21:06
stumbleupon, in my opinion as some one who here with a longer term view , better if

a gradual move up Tomorrow to around £1,50, better to see any sellers cleared at each level.

bunz3
08/2/2021
21:02
SO MANY LARGE BUYS

why they loading up after this rns

Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing



genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a distribution agreement with Beckman Coulter Life Sciences ("Beckman Coulter") for its Genedrive® 96 SARS-CoV-2 Kit. The agreement enables Beckman Coulter to sell and distribute genedrive's high-throughput COVID-19 PCR Kit in the United States and Europe for use on upper respiratory viral samples. The agreement is the result of the collaboration agreement announced in August 2020, under which the companies worked to develop and validate a fully automated PCR process for Beckman Coulter's Biomek automated workstation in conjunction with its RNAdvance Viral XP extraction kit.



The Genedrive® 96 SARS-CoV-2 test is ideally suited for use on the high throughput robotic Biomek i7 instrument. The ready-to-go nature of the test removes many of the fluid dispensing steps required in competitor assays, increasing the overall throughput of the Biomek compared to using a liquid reagent based test formulation. Full automation of the overall PCR workflow can allow laboratories to run large numbers of tests over extended working hours or workstation platforms. Beckman Coulter estimates that this new turnkey solution could process circa 1,000 PCR samples per Biomek workstation installed during a standard 8-hour working day, using just a 0.5 full-time-equivalent in technician time for processing.

bunz3
08/2/2021
21:01
keep trying to deramp ,if you short you losing a lot of money

not interested in 300p , £10 /£12 or higher more of an interest for me
seen that reached at ncyt in months after I bought in at £2,20

When I Seen this RNS


Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing


to come to a distribution with Beckman Coulter


is this one of the best Covid tests that available


AND Tonights tweet



USA Europe

bunz3
08/2/2021
20:50
I hope so, i would like to see it hit 200p tomorrow rather then end of the week ;0)
stumbleupon
08/2/2021
20:48
But hey i won't really give a toss, i be out and will go short.
oilisgold
08/2/2021
20:47
Bunz, i know for a fact, you be out well before 200p and will be on another share doing the same.
oilisgold
08/2/2021
20:11
not interested in 300p , £10 /£12 or higher more of an interest for me
seen that reached at ncyt in months after I bought in at £2,20

When I Seen this RNS


Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing


to come to a distribution with Beckman Coulter


is this one of the best Covid tests that available


AND Tonights tweet



USA Europe

bunz3
08/2/2021
19:31
Looking good here. Onwards and upwards. 200p this week imo
seball
08/2/2021
19:29
Probably more
amaretto1
08/2/2021
19:29
USA market 4 X UK ... alone !!!
amaretto1
08/2/2021
19:24
SO MANY LARGE BUYS

why they loading up after this rns

Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing



genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a distribution agreement with Beckman Coulter Life Sciences ("Beckman Coulter") for its Genedrive® 96 SARS-CoV-2 Kit. The agreement enables Beckman Coulter to sell and distribute genedrive's high-throughput COVID-19 PCR Kit in the United States and Europe for use on upper respiratory viral samples. The agreement is the result of the collaboration agreement announced in August 2020, under which the companies worked to develop and validate a fully automated PCR process for Beckman Coulter's Biomek automated workstation in conjunction with its RNAdvance Viral XP extraction kit.



The Genedrive® 96 SARS-CoV-2 test is ideally suited for use on the high throughput robotic Biomek i7 instrument. The ready-to-go nature of the test removes many of the fluid dispensing steps required in competitor assays, increasing the overall throughput of the Biomek compared to using a liquid reagent based test formulation. Full automation of the overall PCR workflow can allow laboratories to run large numbers of tests over extended working hours or workstation platforms. Beckman Coulter estimates that this new turnkey solution could process circa 1,000 PCR samples per Biomek workstation installed during a standard 8-hour working day, using just a 0.5 full-time-equivalent in technician time for processing.

bunz3
08/2/2021
19:21
USA and Europe


so many wanting shares as Middle of Month draws closer after this rns




David Budd, CEO of genedrive plc, said: "We are very pleased to have the partnership of Beckman Coulter in accessing significant COVID testing opportunities throughout the United States and Europe, where the incidence of COVID continues to escalate and the need for high throughout testing solutions remains a priority. The combination of genedrive and Beckman Coulter products and expertise provides the Company with a new, innovative, and competitive solution, and a new sales channel for the American market, which we did not have previously.



"We are very pleased to now take our initial collaboration and development agreement to the commercial stage. Beckman Coulter is an important and significant company in these core geographies, well suited to promoting, selling, and supporting our products."



The Companies are planning commercial introduction of the Genedrive kit from mid February, following commercial and technical training of the Beckman sale and support organisations.

bunz3
08/2/2021
17:21
This should go 200p in anticipation.
oilisgold
08/2/2021
17:20
Jack , you will get caught pants down and pounded with a lubricant.
oilisgold
08/2/2021
17:15
You wish. 8-)
hazl
08/2/2021
17:04
Tree shake tomorrow ??
jackdaw4243
08/2/2021
16:54
He's not interested in researching l, just prefers to post completely made up comments lolDoesn't have a clue but will post in capital letters so you get the message Ha ha ignore him Better to filter the trolls and let them rot
mcrudden
Chat Pages: Latest  255  254  253  252  251  250  249  248  247  246  245  244  Older